The Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer: a Meta-analysis

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2022 Mar 4

PMID 35245206

Authors

Luca Giovanella

Maria Luisa Garo

Domenico Albano

Rainer Gorges

Luca Ceriani

Affiliations

Soon will be listed here.

Abstract

Objective: In patients with differentiated thyroid cancer (DTC), recurrences may occur in up to 20% and may have a fatal outcome in 10% of cases. Thyroglobulin doubling time (Tg-DT) values may contribute to predict response to treatment and disease recurrence in DTC patients. This study aimed to address the following questions: (1) Are Tg-DT values indicative of response to treatments in patients with DTC (i.e. 'treatment monitoring')?; (2) Is Tg-DT predictive of 2-[18F]fluoro-2-deoxy-d-glucose (2-[18F]FDG) PET/CT in patients with DTC?; (3) Are Tg-DT values predictive of DTC prognosis (i.e. 'prediction')?

Design: Systematic review and meta-analysis.

Methods: Methodology was registered in the PROSPERO database (CRD42021257947). A systematic search was carried out in PubMed, Web Of Science, and Scopus from June to August 2021 without time and language restrictions.

Results: Eleven studies were included for a total of 1421 patients. Positive association between Tg-DT < 1 year and recurrence or disease progression was observed. Tg-DT was found to be related with (2-[18F]FDG) PET/CT results in patients with DTC. The area under the curve was 0.86 (95% CI: 0.83-0.89), sensitivity was 0.84 (0.64;0.94), specificity was 0.71 (0.35; 0.92), DOR was 13.1 (3.1; 55.0), LR+ was 2.9 (1.0; 8.1), LR- was 0.22 (0.1; 0.5). For patients with Tg-DT < 1 year (n = 247), the survival risk ratio was 2.09 (95% CI: 1.49; 2.94).

Conclusions: Tg-DT values are valuable in predicting response to treatment and disease recurrence in patients with DTC, as well as their overall survival. In addition, Tg-DT significantly increases the detection rate of 2-[18F]-FDG PET/CT.

Citing Articles

The impact of qualitative [18F]FDG PET/CT in predicting clinical outcomes of post-surgical differentiated thyroid cancer patients with elevated thyroglobulin and negative radioiodine whole-body scan.

Ha L, Phuong N, Son M BMC Surg. 2024; 24(1):377.

PMID: 39593022 PMC: 11590570. DOI: 10.1186/s12893-024-02675-x.

Role of [F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma.

Zajkowska K, Cegla P, Dedecjus M Cancer Imaging. 2024; 24(1):147.

PMID: 39468677 PMC: 11514821. DOI: 10.1186/s40644-024-00791-8.

Match Point: Nuclear Medicine Imaging for Recurrent Thyroid Cancer in TENIS Syndrome-Systematic Review and Meta-Analysis.

Gelardi F, Lazar A, Ninatti G, Pini C, Chiti A, Luster M J Clin Med. 2024; 13(18).

PMID: 39336848 PMC: 11432630. DOI: 10.3390/jcm13185362.

Diagnostic, Theranostic and Prognostic Value of Thyroglobulin in Thyroid Cancer.

Giovanella L, DAurizio F, Petranovic Ovcaricek P, Gorges R J Clin Med. 2024; 13(9).

PMID: 38730992 PMC: 11084486. DOI: 10.3390/jcm13092463.

Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: a systematic review.

Bellini P, Dondi F, Gatta E, Zilioli V, Albano D, Cappelli C Endocrine. 2024; 84(3):812-821.

PMID: 38265607 DOI: 10.1007/s12020-024-03688-5.

References

Meijer J, le Cessie S, van den Hout W, Kievit J, Schoones J, Romijn J . Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2009; 72(4):534-42. DOI: 10.1111/j.1365-2265.2009.03666.x. View

Rossing R, Jentzen W, Nagarajah J, Bockisch A, Gorges R . Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer. Thyroid. 2016; 26(12):1712-1718. DOI: 10.1089/thy.2016.0031. View

McGee S . Simplifying likelihood ratios. J Gen Intern Med. 2002; 17(8):646-9. PMC: 1495095. DOI: 10.1046/j.1525-1497.2002.10750.x. View

Cappelli G . Mathematical model application to the kinetic study of tumor markers. Int J Biol Markers. 1994; 9(1):8-14. DOI: 10.1177/172460089400900102. View

Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, Szpak-Ulczok S, Puch Z, Kukulska A . 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res. 2009; 2(1):8. PMC: 2739165. DOI: 10.1186/1756-6614-2-8. View

Avram A, Zukotynski K, Nadel H, Giovanella L . Management of Differentiated Thyroid Cancer: The Standard of Care. J Nucl Med. 2021; 63(2):189-195. DOI: 10.2967/jnumed.121.262402. View

Vickers A, Thompson I, Klein E, Carroll P, Scardino P . A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014; 83(3):592-6. DOI: 10.1016/j.urology.2013.09.075. View

Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K . Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984; 199(4):461-6. PMC: 1353366. DOI: 10.1097/00000658-198404000-00014. View

Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H . Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncol Lett. 2019; 17(6):5292-5300. PMC: 6507323. DOI: 10.3892/ol.2019.10180. View

10.

Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y . Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011; 21(7):707-16. DOI: 10.1089/thy.2010.0355. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

12.

Arlen P, Bianco F, Dahut W, DAmico A, Figg W, Freedland S . Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008; 179(6):2181-5. PMC: 2667701. DOI: 10.1016/j.juro.2008.01.099. View

13.

Bidart J, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N . Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999; 45(10):1695-707. View

14.

Angell T, Spencer C, Rubino B, Nicoloff J, LoPresti J . In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014; 24(7):1127-33. DOI: 10.1089/thy.2013.0691. View

15.

Leboulleux S, Dupuy C, Lacroix L, Attard M, Grimaldi S, Corre R . Redifferentiation of a -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. Thyroid. 2019; 29(5):735-742. DOI: 10.1089/thy.2018.0457. View

16.

Giovanella L . Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. Curr Opin Oncol. 2019; 32(1):7-12. DOI: 10.1097/CCO.0000000000000588. View

17.

Giovanella L, Trimboli P, Verburg F, Treglia G, Piccardo A, Foppiani L . Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2013; 40(6):874-80. DOI: 10.1007/s00259-013-2370-6. View

18.

Gion M, Mione R, Barioli P, Dittadi R . Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res. 1996; 16(4B):2279-84. View

19.

Albano D, Tulchinsky M, Dondi F, Mazzoletti A, Bertagna F, Giubbini R . The role of Tg kinetics in predicting 2-[F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. Endocrine. 2021; 74(2):332-339. PMC: 8497300. DOI: 10.1007/s12020-021-02755-5. View

20.

Wassermann J, Bernier M, Spano J, Lepoutre-Lussey C, Buffet C, Simon J . Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. Oncologist. 2015; 21(1):50-8. PMC: 4709201. DOI: 10.1634/theoncologist.2015-0107. View